Shingo Hatakeyama @ShingoHatakeya1

Urologist, M.D. ,Ph.D. Prof., and Chairman, Surgical and Oncological Urology, Kidney transplantation, frailty, clinical statistics, and Glycobiology Hirosaki University, Japan Joined July 2019

Tweets

5K
Followers

2K
Following

1K
Likes

30K

Shingo Hatakeyama @ShingoHatakeya1

16 hours ago

筋層浸潤性膀胱癌の温存療法に対するctDNAの有効性画像より先にctDNAが検出できそう、と言うお話

Enrique Grande @drenriquegrande

a day ago

筋層浸潤性膀胱癌の温存療法に対するctDNAの有効性画像より先にctDNAが検出できそう、と言うお話

0 13 32 3K 9

Download Image

0 0 1 540 0

Shingo Hatakeyama @ShingoHatakeya1

a day ago

明日から、弘前で糖質学会開催させて頂きます。臨床ネタもたくさん出ておりますので、臨床家も基礎研究者もお立ち寄りください。 jscr44.com

0 0 3 487 0

Download Image

Tom Powles @tompowles1

5 days ago

5/5 #ESMO25 The DISCUS trial randomises 3 vs 6 cycles of chemotherapy+sequenced avelumab in M1 UC. Patient reported outcome is the primary endpoint. 3 cycles is likely to be better tolerated but is efficacy compromised? Does this open the door for shorter period of ADC trials

2 11 40 3K 8

Download Image

Tom Powles @tompowles1

5 days ago

4/5 #ESMO25 :POTOMAC (Durvalumab/BCG vs BCG alone in MIBC) is +ve for EFS, but is it practice changing? ALBAN trial (atezo/BCG vs BCG in MIBC-result unknown) is also at ESMO. How will they compare with CREST (sasanlimab/BCG). Will there be consistency or a subgroup who benefit?

1 9 24 3K 4

Download Image

Tom Powles @tompowles1

5 days ago

3/5 IMVIGOR011 #ESMO25 Atezo vs placebo in ctDNA+ve UC post cystectomy hit OS/PFS.It also tracks outcomes in the ctDNA-ve supporting a ctDNA adjusted approach, potentially sparing persistently negative patients adjuvant therapy. What is its relevance in the era of perioparive IO?

2 14 34 3K 6

Download Image

Tom Powles @tompowles1

5 days ago

2/5 KN905 #ESMO25: Perioperative EVP in MIBC shows ⬆️ EFS,OS & pCR vs cystectomy alone in cisplatin ineligible MIBC. Gem/cis durvalumab showed pCR=37% & OS HR of 0.75. Will EVP be much better? Will it only apply to the cisplatin ineligible population? Will we see pembro only arm?

1 16 46 4K 10

Download Image

Tom Powles @tompowles1

5 days ago

Five great UC studies #ESMO25 - 1/5 Disitimab Vedotin (HER2) +Toripalimab vs platinum chemo in 1st line HER2+ve UC is positive for PFS/OS. Press release says ‘This reshapes the global treatment landscape of UC,” which sounds v.good. Can it be better than EVP? Are sfx different?

3 45 139 18K 36

Download Image

Shingo Hatakeyama @ShingoHatakeya1

7 days ago

Accepted ABOi living-donor KT is not associated with an increased risk of post-transplant malignancy.

0 0 2 644 0

Download Image

Shingo Hatakeyama @ShingoHatakeya1

3 weeks ago

という事で、結論は nmCRPC患者におけるARSI間の交差抵抗あり。2剤目のARSI前のPSADTは、治療の有効性を予測するのに役立つ可能性がある、です。結局、nmCRPCの半分に転移あるので、ARSIシークエンスはmCRPC治療と同じなのもしれません。逆に59%でPSADTが短縮していないので、効く方もいます。

Shingo Hatakeyama @ShingoHatakeya1

3 weeks ago

1 0 5 2K 1

Download Image

0 1 10 2K 1

Shingo Hatakeyama @ShingoHatakeya1

3 weeks ago

臨床的意義のある前立腺癌の検出においてT2とdiffusion のMRIは造影MRIを加えたマルチパラメトリックMRIに劣っていない前向き、多施設、非劣性試験 490人差、-0.4パーセントポイント Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis jamanetwork.com/journals/jama/…

0 1 7 816 4

Download Image

Shingo Hatakeyama @ShingoHatakeya1

3 weeks ago

Published Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real‐World Multicenter Study Cancer Medicine 2025 onlinelibrary.wiley.com/doi/10.1002/ca…